Business Wire

MA-TRANSMIT-SECURITY

Share
Transmit Security Expands in Europe

Transmit Security , a leading provider of customer identity and access management (CIAM) SaaS solutions, today announced its significant expansion and growth in Europe to address rapidly growing demand for passwordless customer authentication and other solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220511006152/en/

In January, the company hired Dr. Thore Rabe as the new Vice President and General Manager for Europe, Middle East and Africa (EMEA). Rabe oversees all aspects of Transmit Security’s business in EMEA. Thore has over 20 years leading European divisions at Qumulo, Dell EMC, NetApp, Fujitsu Siemens, and Computer Associates and earned his doctorate in Economic Sciences.

“Our expansion comes at a critical time, not just for us, but for the market here in Europe. With the increase in account takeover fraud , we’re seeing substantial demand for passwordless customer authentication that doesn’t require a specialized app or token,” says Rabe. “The pandemic-fuelled growth in mobile app usage along with the brick-and-mortar return of consumers means businesses need stronger, easy-to-use authentication that works across all of their channels. Our customers know they have to serve their consumers digitally, no matter where they are or what devices they use.”

Consumers around the world report that they prefer better security and smooth customer experience ; businesses are increasingly turning to passwordless authentication as the solution. With the growing demand in Europe, Transmit Security has invested heavily in the region, more than doubling its Europe-based employees and growing by 255% across EMEA, including its corporate headquarters in Tel Aviv.

Transmit Security’s customers in EMEA include HSBC, UBS, Telepass S.p.A., Santander, MetroBank and NN Insurance, and dozens of other regional and global companies. Transmit Security helps its customers in the region address many customer identity challenges, including improving customer experience across their digital channels while strengthening authentication against phishing and other threats. Altogether, the company’s customers in EMEA represent over €330 billion in annual revenues.

Transmit Security is a Platinum Sponsor at the Gartner Identity & Access Management Summit on May 12-13 in London (booth 202). They will be presenting, “Fortify Security and Remove Customer Barriers with Passwordless” on Friday at 2:45pm.

About Transmit Security

Transmit Security is on a mission to revolutionize consumer identity and access management by reimagining customer experience (CX) and eliminating account takeover fraud and similar risks. CX-focused, cybersecurity-conscious businesses rely on Transmit Security to deliver innovative, passwordless digital identity journeys for their consumers across all channels and devices. Transmit Security’s customers are responsible for more than $1.3 trillion in annual commerce and include many of the largest banks, insurers, and retailers, along with many other leading brands.

For more information, please visit www.transmitsecurity.com .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release

Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played

Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release

At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will

Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release

Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye